← All trials
NCT06422273
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2024
- Primary completion
- Apr 30, 2025
- Completion date
- Apr 30, 2026
- First posted
- May 20, 2024
- Last posted
- May 20, 2024
- Enrollment
- 94
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The Spectrum Health GroupLead sponsor
- The Spectrum Health GroupSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.